PDS Biotechnology PDSB shares are up on Wednesday as the company announced the publication of clinical and immunological ...
Stocktwits on MSN
PDSB stock hits 37-week high — here’s the latest on its therapy to treat metastatic colorectal cancer
The trial focused on patients with microsatellite-stable or mismatch repair-proficient metastatic colorectal cancer with liver metastases ・The treatment delivered an ORR of nearly 78%, compared to 35% ...
View PDS Biotechnology Corp. PDSB stock quote prices, financial information, real-time forecasts, and company news from CNN.
Detailed price information for Pds Biotechnology Corp (PDSB-Q) from The Globe and Mail including charting and trades.
PDS Biotechnology (NASDAQ:PDSB), a clinical-stage immunotherapy company focused on innovative oncology and infectious disease solutions, released its second quarter results on August 13, 2025, for the ...
This period saw the company reduce total operating expenses by 12.6% (GAAP), driven mainly by lower personnel and professional service fees. Research and development, or R&D, costs (GAAP) decreased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results